Roche Says Illumina Takeover Would Hasten Sequencing’s Path To Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
With $5.7 billion hostile takeover attempt for next-generation gene sequencing powerhouse Illumina, Roche says it is uniquely situated to push sequencing into the routine clinical diagnostics space. But Illumina is resisting, which could push up the price and draw out the process.